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Abstract
Background: The majority of women with ovarian cancer are diagnosed in late stages, and the
mortality rate is high. The use of biomarkers as prognostic factors may improve the treatment and
clinical outcome of these patients. We performed an external validation of the potential
biomarkers CLU, ITGB3, CAPG, and PRAME to determine if the expression levels are relevant to
use as prognostic factors.
Methods: We analysed the gene expression of CLU, ITGB3, CAPG, and PRAME in 30 advanced
staged serous adenocarcinomas with quantitative real-time polymerase chain reaction (QPCR) and
the protein levels were analysed in 98 serous adenocarcinomas with western blot for
semiquantitative analysis. Statistical differences in mRNA and protein expressions between
tumours from survivors and tumours from deceased patients were evaluated using the Mann-
Whitney U test.
Results: The gene and protein ITGB3 (Integrin beta 3) were significantly more expressed in
tumours from survivors compared to tumours from deceased patients, which is in concordance
with our previous results. However, no significant differences were detected for the other three
genes or proteins CLU, CAPG, and PRAME.
Conclusion:  The loss of ITGB3 expression in tumours from deceased patients and high
expression in tumours from survivors could be used as a biomarker for patients with advanced
serous tumours.
Background
Ovarian carcinoma is the fifth most common cause of
cancer death among women in Western Europe and the
United states [1,2]. The most common type is epithelial
ovarian cancer, which has several histopathological sub-
types including serous, mucinous, endometrioid, and
clear cell carcinomas. Among these, serous papillary ade-
nocarcinoma is the most common form accounting for
approximately 50% of cases [3].
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The majority of women with ovarian cancer are diagnosed
in late stages, and these patients are treated similarly with
tumour reductive surgery followed by chemotherapy.
However, even though patients with stage III-IV tumours
undergo extensive therapy, the mortality rate is high, and
only 30% of patients survive more than five years after
diagnosis [4]. The prognostic factors used today, such as
surgical stage, volume of residual tumour after primary
surgery, and histologic grade, are insufficient to optimise
and individualise the treatment. There is an urgent need to
better classify these tumours to improve the treatment and
clinical outcome of patients.
The use of novel biomarkers as prognostic factors may
facilitate identification of patients who are likely to
relapse and die of the disease. Expression profiles have
been used to identify genes involved in ovarian tumour
initiation and progression. We have previously used
expression arrays to detect potential biomarkers with
prognostic relevance [5]. However, there is a limited over-
lap of data among expression analyses of ovarian carcino-
mas owing to several factors [6]. First, the number of
tumours studied is low and consists of different stages and
mixtures of histopathological subtypes. Second, different
microarray technology platforms and statistics are used,
and the definition of different endpoints varies in the
studies. The extensive knowledge about differences in
microarray results suggests that external validations are
required to verify if the data are relevant to use. Our pre-
vious analysis demonstrated differences in expression
between tumours from survivors and tumours from
deceased patients, including four cancer-related genes,
ITGB3, CLU, CAPG, and PRAME [5]. We further estab-
lished the significant differences in expression levels for
the corresponding proteins [7]. Further validation of the
gene and protein expressions in an external validation set
is necessary, to clarify if the expression levels are usable as
biomarkers. The protein expressions of these potential
biomarkers may also be related to the tumours biological
properties.
Integrin beta 3 (ITGB3) was more expressed in tumours
from survivors in our previous studies. Integrins are
known to participate in cell adhesion, and work as recep-
tors in cell-surface mediated signalling, through binding
with different ligands in focal adhesions [8-10]. Clusterin
(CLU), also more expressed in tumours from survivors in
our previous studies, seems to have divergent functions in
cells. This is probably due to different isoforms, one
secreted/cytoplasmic form (sCLU/cCLU) with chaperone
activity involved in tumour progression, and one nuclear
form (nCLU) with proapoptotic function [11-13]. Cap-
ping protein (actin filament) gelsolin-like (CAPG), which
was more expressed in tumours from deceased patients in
our studies, belongs to the gelsolin protein superfamily.
This group of proteins control actin organisation, and
CAPG contributes to the control of actin-based motility in
cells by capping the barbed ends of actin filaments
[14,15]. Preferentially expressed antigen in melanoma
(PRAME) is a repressor of retinoic acid receptor signalling
[16]. In our previous studies, PRAME was detected as
more expressed in tumours from deceased patients com-
pared to tumours from survivors.
In this study, we performed an external validation of the
four genes and proteins in a new set of advanced ovarian
serous adenocarcinomas to determine if differences in
expression levels are relevant to use as prognostic markers.
Methods
Patient and tumour material
In this study, 98 advanced stage (III or IV) serous papillary
adenocarcinomas of the ovary were analyzed (Table 1).
The tumours were randomly selected and adjusted to sim-
ilar size of tumours from survivors and tumours from
deceased patients. Patients who survived five years or
more after the initial diagnosis were considered as survi-
vors and all deceased patients in the study succumbed to
cancer. Surgical staging of the tumours was performed
according to International Federation of Gynaecology and
Obstetrics (FIGO) standards, and patients with no macro-
scopic residual tumour were classified as radically oper-
ated. The tumours were removed at primary surgery and
secured for pathology examination, RNA, and protein
extraction. After surgery, patients were treated with plati-
num based chemotherapy, either with a combination of
farmorubicine, carboplatin, and cyclophosphamide, or
with a combination of paclitaxel and carboplatin. The
tumours were collected from patients diagnosed between
1993 and 2003 at Sahlgrenska University Hospital,
Gothenburg, Sweden, and the study was approved by the
local ethics committee. A pathologist reviewed all
tumours according to the treatment protocol for gynaeco-
logical malignancies in western Sweden. Specimen
imprints for cytologic evaluation were performed to verify
the presence of tumour cell content, and only tumours
containing at least 50% tumour cells were included.
Quantitative real-time polymerase chain reaction (QPCR)
Thirty tumours from patients treated with paclitaxel and
carboplatin were analysed with QPCR, performed as
described by Partheen et al. [7]. Briefly, total RNA was iso-
lated from frozen tumours by homogenisation with TRI-
zol Reagent (Invitrogen, Carlsbad, CA, USA) and then
extracted with RNeasy mini kit (Qiagen, Valencia, CA,
USA). High-quality RNA was obtainable from 30 samples
and used in the analysis. From each tumour sample 0.5 g
of total RNA was reverse transcribed in duplicate. Each
cDNA sample was analysed once by real-time PCR, giving
two data points for each tumour sample. The cDNA wereBMC Cancer 2009, 9:336 http://www.biomedcentral.com/1471-2407/9/336
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detected with SYBR Green I. Two stable reference genes
were used for normalisation, GAPDH and -actin from
the Human Endogenous Control Gene Panel (TATAA Bio-
center, http://www.tataa.com). The efficiency of each
QPCR assay was estimated from the slope of a standard
curve generated from the serial dilution of purified PCR
products. The assays for CLU and ITGB3 showed PCR effi-
ciencies close to 80%, and for CAPG and PRAME 90%.
These values were used for subsequent calculations. For
each assay the average Ct value for each tumour sample
was converted to relative copy numbers. The data were
then normalised by the geometric average of the two ref-
erence genes [17].
Western blot
Western blot was performed on 98 tumour samples, each
in duplicate as described by Partheen et al. [7]. Briefly, the
frozen samples were homogenised with RIPA followed by
centrifugation. The samples were diluted in SDS sample
buffer with and without 10% 2-mercaptoethanol and
heated at 97°C for 5 minutes. The unreduced samples
(without 2-mercaptoethanol) were used to detect ITGB3.
Total protein was loaded into each lane on a 10% Crite-
rion™ precast gel (BIO-RAD laboratories, Hercules, CA,
USA). The proteins were transferred to nitrocellulose
membranes (BIO-RAD) and blocked overnight at 4°C in
5% non-fat milk in 10 mM Tris buffered saline (TBS).
The membranes were incubated in TBS containing
0,05%Tween 20 with the following primary antibodies:
chicken polyclonal to CAPG (1:3000, ab14235, Abcam,
Cambridge, UK), rabbit polyclonal to PRAME (1:1000,
ab32185, Abcam), mouse monoclonal to CLU (1:15 000,
clone 41D, Upstate Biotechnology, Lake Placid, NY, USA),
ITGB3 (1:1000, MAB1974, Chemicon, Temecula, CA,
USA) and GAPDH as a relative loading control (1:15 000,
ab8245, Abcam). Proteins were visualised by chemilumi-
nescence, using horseradish peroxidase-linked (HRP) sec-
ondary antibodies; goat anti-rabbit (1:5000, ab6721,
Abcam), anti-chicken (1:3000, GAYFC-HRP, Genway Bio-
tech, San Diego, CA, USA) and anti-mouse (1:5000, sc-
2005, Santa Cruz Biotechnology Inc). The membranes
were exposed to Amersham Hyperfilm™ ECL (Amersham,
Buckinghamshire, UK). The optical density from each
band was measured using the software package Quantity
One (BIO-RAD) and used for semiquantitative analysis of
the proteins. The CLU antibody used detects all isoforms
of the protein, and the mature form of CLU at approxi-
mately 40 kDa was analysed in this study [18]. An internal
reference sample containing pooled protein from ovarian
Table 1: Summary of clinicopathologic characteristics of the patients
Tumours
(from survivors/deceased patients)
Total Tumours 98 (48/50)
Tumours used in QPCR analysis 30 (15/15)







Radically operated 20 (13/7)
Residual tumour 75 (34/41)





Not available 2 (2/0)
Treatment
farmorubicine, carboplatin and cyclophosphamide 31 (16/15)
paclitaxel and carboplatin 67 (32/35)BMC Cancer 2009, 9:336 http://www.biomedcentral.com/1471-2407/9/336
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tumours, same on each blot, was used as a standard for
quantification and was given the value 1. The mean value
of the duplicates was calculated and used in the analysis.
Statistical analysis
Statistical analysis of the data was performed using SPSS
for Windows (version 12.0.1). The tumours used in the
protein analysis were from patients treated with slightly
different carboplatin-based chemotherapies. To check if
the two treatment groups could be combined in the statis-
tical analysis, treatment was tested as a 2-level factor, as
well as an interaction with protein expression in logistic
regression models with survival as response. Due to the
skewed expression distributions, the logarithms of pro-
tein expressions were used as explanatory variables in the
model, and nonparametric tests were used in the analysis
of statistical differences.
Statistical differences in mRNA and protein expressions
between tumours from survivors and tumours from
deceased patients were evaluated using the Mann-Whit-
ney U test. Logistic regression was performed on logarith-
mic values of protein expressions and the prognostic
factors age, stage and surgery outcome to define if these
factors contributes significantly to the prediction of sur-
vival. The relation between expressions measured with
QPCR and western blot was evaluated with bivariate cor-
relation using Spearman correlation coefficient. We used
Kaplan-Meier survival curves to show differences in clini-
cal outcome between patients with tumours that
expressed high alternatively low levels of ITGB3 mRNA or
protein, using cut-off values at 0.29 and 0.43 respectively,
based on the detected relative expression levels. A log-
rank test was used to compare the curves. A value of p <
0.05 was considered to be significant.
Results
The gene ITGB3 was detected as differently expressed
The expression of CLU, ITGB3, CAPG, and PRAME was
investigated to study differences in expression levels
between tumours from survivors and tumours from
deceased patients. The four genes were analysed with
QPCR in 30 of the 98 serous adenocarcinomas from
patients treated with paclitaxel and carboplatin. The
number of tumours analysed was reduced, because the
RNA quality did not reach the desirable level in 68 sam-
ples. The expression in tumours from survivors and in
tumours from deceased patients were compared, and
ITGB3 was significantly more expressed in tumours from
survivors (p  = 0.004) (Figure 1). The best separation
between the two groups was obtained with a cut-off value
of the relative expression at 0.29 (Figure 1A). Only three
tumours from survivors expressed ITGB3 less than 0.29
and three tumours from deceased patients more than
0.29. No statistical differences were detected for the other
three genes analysed: CAPG (p = 0.24), CLU (p = 0.76),
and PRAME (p = 0.52).
Relative mRNA copy numbers for the genes Figure 1
Relative mRNA copy numbers for the genes. Relative mRNA copy numbers as log2 values for the genes A) ITGB3 (sig-
nificantly differently expressed, p = 0.004) B) CLU C) CAPG and D) PRAME. Each plot shows the medians (centre lines), inter-
quartile ranges (boxes), largest and smallest values (whiskers) that are not outliers (circles), or extreme values (stars) within a 
category.BMC Cancer 2009, 9:336 http://www.biomedcentral.com/1471-2407/9/336
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The protein ITGB3 was detected as differently expressed
The proteins CLU, ITGB3, CAPG, and PRAME were exam-
ined with western blot for semiquantitative measure-
ments of each protein in 98 tumours (Figure 2). Type of
patient treatment could be ignored in the analysis, since
no significant effects on protein expressions were
detected. A significant difference in expression between
tumours from survivors and tumours from deceased
patients was detected for ITGB3 (p = 0.005), but not for
the other proteins, CLU (p = 0.15), PRAME (p = 0.62), and
CAPG (p  = 0.24). The most optimal cut-off value for
ITGB3 that separated survivors and deceased patients
turned out to be 0.43 (logarithmic value -0.87). The logis-
tic regression analysis using age, stage, surgery outcome
and protein expressions showed that ITGB3 (p = 0.002)
and survival (p = 0.013) was independent factors to pre-
dict survival. In addition, significant differences of ITGB3
expression were also detected when tumours were divided
according to treatment, with p = 0.05 for paclitaxel and
carboplatin treated patients and p = 0.04 for farmorubi-
cine-, carboplatin-, and cyclophosphamide-treated
patients.
The relative expression of ITGB3 mRNA and protein cor-
related well (p = 0.027). Both mRNA and protein expres-
sions at low levels are dominated by tumours from
deceased patients, as illustrated in Figure 3A. Kaplan-
Meier survival curves for high versus low expression of
ITGB3 mRNA and protein are shown in Figure 3B and 3C,
respectively. There was a significant difference in survival
for tumours with high versus low expression of the mRNA
and protein.
Discussion
In this study, we performed an external validation of four
potential prognostic biomarkers, ITGB3, CLU, CAPG, and
PRAME, in advanced ovarian serous adenocarcinomas.
We compared the gene and protein expression levels
between tumours from survivors and tumours from
deceased patients, and ITGB3 was the one found as differ-
ently expressed. The clinical outcome of patients with
advanced ovarian adenocarcinoma is difficult to predict at
an individual level, and ITGB3 could be a complementary
potential biomarker for patients with serous tumours.
This is of importance because an improvement of the
prognostic factors may make it possible to optimise
patients' treatment. The differences were detected for both
Relative protein expression for the proteins Figure 2
Relative protein expression for the proteins. Relative protein expression of A) ITGB3a (significantly differently expressed, 
p = 0.005) B) CLU C) CAPG and D) PRAME. Each plot shows the medians (centre lines), interquartile ranges (boxes), largest 
and smallest values (whiskers) that are not outliers (circles), or extreme values (stars) within a category. A representative 
immunoblot is shown for ITGB3, where GAPDH was used as loading control and tumours from survivors (S) and deceased (D) 
patients are indicated. aIn the figure, ITGB3 values for two survivors and one deceased patients were excluded due to 
extremely high values.BMC Cancer 2009, 9:336 http://www.biomedcentral.com/1471-2407/9/336
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the gene and the protein expressions, which strengthens
the credibility of our results.
A limitation in many studies of biomarkers, with microar-
ray and other methods, is the lack of follow-up with exter-
nal validation of significant findings. Consequently, the
insignificant results for CLU, CAPG, and PRAME in the
present study highlight the importance of verifying data in
an external validation set of tumours, although, the
number of tumours analysed with QPCR in this study was
low, and small groups may have had an impact on the
results. However, earlier studies have reported CLU as
down-regulated and CAPG and PRAME as up-regulated in
advanced carcinomas compared to early tumours or nor-
mal tissue [19-25]. Even though we did not detect any dif-
ferences in relation to survival in our analysis, the
expression of CLU, CAPG, and PRAME might still be asso-
ciated with the development and progression of serous
ovarian adenocarcinomas. Concerning ITGB3, an evalua-
tion in the reverse order, where the patients are classified
depending on the tumours' ITGB3 expression, could
determine if it is possible to distinguish patients who will
respond to standard treatment from those who will not.
The gene ITGB3 encodes the beta chain of two integral
cell-surface glycoproteins, v3 and GPIIb/IIIa, of which
v3 is expressed on endothelial and tumour cells [26].
As molecules involved in cell adhesion and cell signalling,
integrins have an important role in various carcinomas.
The expression of v3 integrins has been linked to bad
prognosis for breast cancer and melanoma patients, but
the relation to ovarian tumours needs further clarification
[27,28]. The expression of v3 integrins has been
detected as less frequent in ovarian epithelial tumours of
low malignant potential (LMP) in contrast to ovarian car-
cinomas [29]. Controversially, Maubant et al. [30] found
a significantly less frequent expression of the 3 subunit
in grade 3 ovarian tumours compared to grade 1 and 2
tumours, and less expression in peritoneal metastasis
compared to primary tumours. Nevertheless, they did not
find any correlation to survival, as we did in our study.
The use of tumours with different histological subtypes
and stages in their analysis may explain the inconsistent
findings compared with our results, since we used only
advanced serous adenocarcinomas. Further, ITGB3 pro-
tein expression have been detected in normal ovarian epi-
thelium and highly differentiated ovarian carcinomas, but
are lacking in most of the less-differentiated tumours [31].
Regeneration of normal ovarian epithelial cells is a con-
tinuous process due to wound healing after ovulation.
This process involves adhesion, spreading, and prolifera-
tion of cells, all features that could involve integrins. The
expression of ITGB3 in the normal ovarian epithelium
and its expression in well-differentiated ovarian carcino-
mas may reflect the preservation of normal cell properties.
Visualization of differences in ITGB3 expression levels  between survivors and deceased patients Figure 3
Visualization of differences in ITGB3 expression lev-
els between survivors and deceased patients. A) The 
logarithmic relative values of protein and mRNA expressions 
from the same tumour plotted against each other. B) Kaplan-
Meier survival curve for ITGB3 mRNA and C) the protein 
ITGB3.BMC Cancer 2009, 9:336 http://www.biomedcentral.com/1471-2407/9/336
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The expression of ITGB3 in tumours from survivors in our
study may indicate that these tumour cells still retain nor-
mal cell properties, and are therefore less aggressive.
Moreover, v3 may have different function in various
tissues, which may partly explain the divergent results of
v3 expression linked to bad prognosis in other cancers,
such as breast cancer and melanoma [27,28]. Therefore,
the use of ITGB3 as a biomarker may only have clinical
relevance in ovarian adenocarcinomas.
Normal adherent cells must be anchored to the extracellu-
lar matrix (ECM) to survive and proliferate. Ligated v3
activates cell survival pathways and suppresses proapop-
totic signalling, while inactive unligated v3 promotes
apoptosis [32,33]. Maubant et al. [34] used a sensitive
ovarian cancer cell line and its cisplatin-resistant counter-
part to study the expression of v3 and v5. They
showed that three days after plating, the v subunit asso-
ciated with the 3 subunit on the surface of sensitive cells,
but it associated with both 3 and 5 on the surface of
resistant cells. Consequently, ITGB3 could have a dual
role in cancer. At its primary site, the protein favours a
good prognosis, but as soon as the tumour cell has lost its
attachment, the cell will be able to metastasise and
progress at a distant site. This dual role of the protein may
have an impact on the use of ITGB3 as a biomarker.
Finally, the function of ITGB3 as a biomarker in ovarian
adenocarcinoma may be influenced by other factors in the
tumours. One such factor is the up-regulation of v3
integrin in low HRG/NRG1-expressing breast cancer cell
lines [35]. These cell lines are highly sensitive to treatment
with paclitaxel. The up-regulation of v3 integrin and
low expression of HRG/NRG1 in cancer cells could be a
novel molecular marker of chemosensitivity. The correla-
tion of HRG/NRG1 and ITGB3 expression might be rele-
vant to study in ovarian tumours as well, or there might
be other unknown factors that regulate the impact of
ITGB3 as a biomarker.
Conclusion
In conclusion, ITGB3 was significantly differently
expressed between tumours from survivors and tumours
from deceased patients. The differences were detected for
both gene and protein levels in our external validation set
of advanced serous ovarian adenocarcinomas. The loss of
ITGB3 expression in tumours from deceased patients and
high expression in tumours from survivors could be used
as a biomarker for patients with advanced serous
tumours. Prospective evaluation of ITGB3 expression lev-
els could determine if it is possible to distinguish patients
who will respond to standard treatment from those who
will not. It would also be worth considering a study of
ITGB3 expression in stage I and stage II serous ovarian
tumours, and in other histopathological subtypes. In
future, it may be that patients who respond to standard
therapy could be treated with a more moderate combina-
tion of anti-cancer agents, and higher-risk patients might
be offered additional chemotherapy and more frequent
follow up at an initial state.
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